Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations

Cancer

Volumn 122, Issue 5, 2016, Pages 702-711

  Ross, Jeffrey S ^a,b   Wang, Kai ^b   Khaira, Depinder ^b   Ali, Siraj M ^b   Fisher, Huge A G ^a   Mian, Badar ^a   Nazeer, Tipu ^a   Elvin, Julia A ^b   Palma, Norma ^b   Yelensky, Roman ^b   Lipson, Doron ^b   Miller, Vincent A ^b   Stephens, Philip J ^b   Subbiah, Vivek ^c   Pal, Sumanta K ^d  

^a ALBANY MEDICAL COLLEGE   (United States)

^b FOUNDATION MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

bladder cancer; comprehensive genomic profiling; cyclin dependent kinase inhibitor 2A (CDKN2A); fibroblast growth factor receptor (FGFR); metastatic; micropapillary

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FGFR3 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CDKN2A GENE; CLINICALLY RELEVANT GENOMIC ALTERATION; COMPREHENSIVE GENOMIC PROFILING; CONTROLLED STUDY; COPY NUMBER VARIATION; ERBB2 GENE; FEMALE; FGFR3 GENE; GENE; GENE AMPLIFICATION; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC PROCEDURES; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PIK3CA GENE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; FACTUAL DATABASE; GENE FUSION; GENE REARRANGEMENT; GENETIC VARIATION; GENETICS; METASTASIS; MUTATION; PATHOLOGY; PROTO ONCOGENE; SECONDARY; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, TRANSITIONAL CELL; DATABASES, FACTUAL; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE FUSION; GENE REARRANGEMENT; GENES, ERBB-2; GENES, P16; GENES, P53; GENETIC VARIATION; HUMANS; MALE; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; URINARY BLADDER NEOPLASMS;

EID: 84958863406     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29826     Document Type: Article

References (56)

1. Abdollah F, Gandaglia G, Thuret R, et al., Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013; 37: 219-225.
2. Kaufman DS, Shipley WU, Feldman AS,. Bladder cancer. Lancet. 2009; 374: 239-249.
3. Noon AP, Catto JW,. Bladder cancer in 2012: challenging current paradigms. Nat Rev Urol. 2013; 10: 67-68.
4. Ploeg M, Aben KK, Kiemeney LA,. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27: 289-293.
5. Calabro F, Sternberg CN,. Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2009; 55: 348-358.
6. Pal SK, Milowsky MI, Plimack ER,. Optimizing systemic therapy for bladder cancer. J Natl Compr Canc Netw. 2013; 11: 793-804.
7. Vashistha V, Quinn DI, Dorff TB, Daneshmand S,. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer. 2014; 14: 966.
8. Alvarez RH, Valero V, Hortobagyi GN,. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010; 28: 3366-3379.
9. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK,. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014; 14: 535-546.
10. Chabner BA,. Early accelerated approval for highly targeted cancer drugs. N Engl J Med. 2011; 364: 1087-1089.
11. Teply BA, Kim JJ,. Systemic therapy for bladder cancer-a medical oncologist's perspective. J Solid Tumors. 2014; 4: 25-35.
12. Ghosh M, Brancato SJ, Agarwal PK, Apolo AB,. Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014; 26: 305-320.
13. Gorin MA, Ayyathurai R, Soloway MS,. Diagnosis and treatment of bladder cancer: how can we improve? Postgrad Med. 2012; 124: 28-36.
14. Mitra AP, Datar RH, Cote RJ,. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol. 2006; 24: 5552-5564.
15. Ross JS, Cohen MB,. Detecting recurrent bladder cancer: new methods and biomarkers. Expert Rev Mol Diagn. 2001; 1: 39-52.
16. Sapre N, Herle P, Anderson PD, Corcoran NM, Hovens CM,. Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder. Pathology. 2014; 46: 274-282.
17. Sjodahl G, Lovgren K, Lauss M, et al., Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol. 2013; 183: 681-691.
18. Solomon JP, Hansel DE,. Prognostic factors in urothelial carcinoma of the bladder: histologic and molecular correlates. Adv Anat Pathol. 2015; 22: 102-112.
19. Faltas BM, Karir BS, Tagawa ST, Rosenberg JE,. Novel molecular targets for urothelial carcinoma. Expert Opin Ther Targets. 2015; 19: 515-525.
20. Knowles MA, Hurst CD,. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015; 15: 25-41.
21. Ross JS, Wang K, Al-Rohil RN, et al., Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol. 2014; 27: 271-280.
22. Frampton GM, Fichtenholtz A, Otto GA, et al., Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31: 1023-1031.
23. Compeau PE, Pevzner PA, Tesler G,. How to apply de Bruijn graphs to genome assembly. Nat Biotechnol. 2011; 29: 987-991.
24. Forbes SA, Bindal N, Bamford S, et al., COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011; 39 (Database issue): D945-D950.
25. Porter MP, Kerrigan MC, Donato BM, Ramsey SD,. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. 2011; 29: 252-258.
26. von der Maase H, Sengelov L, Roberts JT, et al., Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602-4608.
27. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507: 315-322.
28. Cazier JB, Rao SR, McLean CM, et al., Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat Commun. 2014; 5: 3756.
29. Cha EK, Bochner BH,. Re: whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Eur Urol. 2015; 67: 350-351.
30. Bamford S, Dawson E, Forbes S, et al., The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004; 91: 355-358.
31. Janku F, Tsimberidou AM, Garrido-Laguna I, et al., PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011; 10: 558-565.
32. Ali SM, Miller VA, Ross JS, Pal SK,. Exceptional response on addition of everolimus to taxane in urothelial carcinoma bearing an NF2 mutation. Eur Urol. 2015; 67: 1195-1196.
33. Turner N, Grose R,. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010; 10: 116-129.
34. di Martino E, Tomlinson DC, Knowles MA,. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol. 2012; 2012: 429213.
35. Palma N, Morris JC, Ali SM, Ross JS, Pal SK,. Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating mutation and amplification. Eur Urol. 2015; 68: 168-170.
36. Sequist LV, Cassier P, Varga A, et al., Abstract CT326: phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res. 2014; 74: CT326.
37. Ross JS, Wang K, Gay LM, et al., A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res. 2014; 20: 68-75.
38. Amin MB,. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009; 22 (suppl 2): S96-S118.
39. Lopez JI, Elorriaga K, Imaz I, Bilbao FJ,. Micropapillary transitional cell carcinoma of the urinary bladder. Histopathology. 1999; 34: 561-562.
40. Kamat AM, Dinney CP, Gee JR, et al., Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007; 110: 62-67.
41. Samaratunga H, Khoo K,. Micropapillary variant of urothelial carcinoma of the urinary bladder: a clinicopathological and immunohistochemical study. Histopathology. 2004; 45: 55-64.
42. Chen PC, Yu HJ, Chang YH, Pan CC,. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol. 2013; 66: 113-119.
43. Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN,. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011; 60: 350-357.
44. Marin AP, Arranz EE, Sanchez AR, Aunon PZ, Baron MG,. Role of anti-Her-2 therapy in bladder carcinoma. J Cancer Res Clin Oncol. 2010; 136: 1915-1920.
45. Chmielecki J, Ross JS, Wang K, et al., Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist. 2015; 20: 7-12.
46. Ross JS, Wang K, Sheehan CE, et al., Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res. 2013; 19: 2668-2676.
47. Bose R, Kavuri SM, Searleman AC, et al., Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013; 3: 224-237.
48. Herter-Sprie GS, Greulich H, Wong KK,. Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front Oncol. 2013; 3: 86.
49. Mazieres J, Peters S, Lepage B, et al., Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013; 31: 1997-2003.
50. Tsai YS, Cheng HL, Tzai TS, Chow NH,. Clinical significance of ErbB receptor family in urothelial carcinoma of the bladder: a systematic review and meta-analysis. Adv Urol. 2012; 2012: 181964.
51. Vornicova O, Hershkovitz D, Yablonski-Peretz T, Ben-Itzhak O, Keidar Z, Bar-Sela G,. Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F. Oncologist. 2014; 19: 1006-1007.
52. Greulich H,. The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer. 2010; 1: 1200-1210.
53. Greulich H, Kaplan B, Mertins P, et al., Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012; 109: 14476-14481.
54. Lee JC, Vivanco I, Beroukhim R, et al., Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006; 3: e485.
55. Ali SM, Alpaugh RK, Downing SR, et al., Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. J Clin Oncol. 2014; 32: e88-e91.
56. Guancial EA, Rosenberg JE,. The role of genomics in the management of advanced bladder cancer. Curr Treat Options Oncol. 2015; 16: 319.